MedPlus Health Services Limited has informed stock exchanges that its subsidiary, Optival Health Solutions Private Limited, has received three suspension orders for drug licenses of its stores in the state of Karnataka. The updates have been disclosed under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Details of the Suspension Orders
The company stated that the suspension orders affect the following stores:
- Jayanagar 9th Block and T R Nagar, Bangalore
- Issuing Authority: Assistant Director, Drugs Control Administration, Bangalore Circle-3
- Suspension Period: Three days each
- Applicable Law: Rule 65 of the Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945
- Potential Revenue Loss: ₹2.29 lakh and ₹0.53 lakh, respectively
- Shiggon, Haveri, Karnataka
- Issuing Authority: Assistant Director, Drugs Control Administration, Haveri Circle
- Suspension Period: Three days
- Potential Revenue Loss: ₹0.42 lakh
The orders were received on December 23, 2025.
Financial Impact
MedPlus noted that the monetary impact is limited, with a potential revenue loss totaling approximately ₹3.24 lakh across the affected stores.
Regulatory Compliance
The disclosure has been made following SEBI Circulars dated July 13, 2023, and December 31, 2024, and the details will also be available on the company’s official website (www.medplusindia.com) as well as on BSE and NSE portals.
MedPlus operates a large network of pharmacy stores across India, and the company has emphasized that these temporary suspensions will not significantly affect overall operations.
